Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports

Figure 1 A 58-year-old female diagnosed with extensively drug-resistant tuberculosis and treated with bedaquiline for 36 wk. A: The QT interval with Fridericia's correction remained relatively stable during bedaquiline treatment, not exceeding 500 ms; B: Computed tomography (CT) on May 24, 2018 (before bedaquiline-containing treatment); C: CT on January 10, 2019 (week 23); D: CT on January 13, 2020 (after 36-wk bedaquiline-containing treatment and 36-wk background treatment); E: Treatment regimen and episode. QTcF: QT interval with Fridericia's correction.

Figure 2 An 18-year-old female diagnosed with pre-extensively drug-resistant tuberculosis and treated with bedaquiline for 36 wk. A: The QT interval with Fridericia's correction remained relatively stable during bedaquiline treatment, not exceeding 500 ms; B: Computed tomography (CT) on April 10, 2019 (before bedaquiline-containing treatment); C: CT on October 24, 2019 (week 24); D: CT on March 12, 2020 (after the completion of 36-wk bedaquiline-containing treatment); E: Treatment regimen and episode. QTcF: QT interval with Fridericia's correction.